A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF AEROVANC FOR THE TREATMENT OF PERSISTANT METHICILLIN-RESISTANT Staphylococcus aureus LUNG INFECTION IN CYSTIC FIBROSIS PATIENTS; SAV005-04
Brief description of study
TBD
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
CF, lung, MRSA
-
Age: - 99 Years
-
Gender: All
Updated on
30 Jan 2020.
Study ID: 828169